Lymphocyte Counts in Immune Thrombocytopenic Purpura

• Sponsor: Assiut University (Other)
• Overall Status: Unknown status
• CT.gov ID: NCT03244410
• Collaborator: (none)
• Enrollment: 1
• Anticipated Duration (Months): 15

Study Details

Study Description

Brief Summary

• immune thrombocytopenic purpura is an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number (cooper N et al 2006)

• recent studies have demonstrated that the pathogenesis of ITP envolves multifactorial autoimmune mechanisms of both humoral and cellular immunity and that acute and chronic forms may represent two distinct immunopathological disorders ( cooper N et al 2006) ( Gern Sheimer T 2009 )

Condition or Disease	Intervention/Treatment	Phase
Thrombocytopenic Purpura	Diagnostic Test: complete blood picture

Detailed Description

Immune thrombocytopenic purpura is an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number ( Cooper N et all 2006) platelet surface membrane proteins become antigenic for unknown reasons, leading to stimulation of the immune system, auto antibodies production and platelet destruction ( Gasbarrini A et all 2000) It is associated with the production of auto antibodies directed against platelet glycoprotein complex 2b/3a and/or 1b/1x , resulting in accelerated destruction of platelets by the reticular endothelial system via the activity of Fcc receptor bearing phagocytic cells ( Provan & Newland et al 2002) Recent studies have demonstrated that the pathogenesis of ITP envolves multifactorial autoimmune mechanisms of both humoral and cellular immunity and that acute and chronic forms may represent two distinct immunopathological disorders ( Cooper N et al 2006) ( Gern Sheimer T 2009)

There are many phases of the disease:

1. Newly diagnosed ITP : for all cases at diagnosis.

2. persistent ITP: for patients with ITP between 3 to 12 months.

3. chronic ITP: for patients with ITP lasting more than one year ( blood journal 2009).

• Although lymphocytopenia is a commonly reported feature of many chronic autoimmune disorders, differential white cell counts at presentation have seldom been evaluated as predictors for development of chronic ITP ( Deel MD et al 2013) (Ahmed et al 2010)

Study Design

• Study Type: Observational
• Anticipated Enrollment: 1 participants
• Observational Model: Other
• Time Perspective: Other
• Official Title: Initial Lymphocyte Counts Predictive Value in Immune Thrombocytopenic Purpura
• Anticipated Study Start Date: Oct 1, 2017
• Anticipated Primary Completion Date: Dec 1, 2018
• Anticipated Study Completion Date: Jan 1, 2019

Arms and Interventions

Arm	Intervention/Treatment
immune thrombocytopenic purpura immune thrombocytopenic purpura an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number we used complete blood picture	Diagnostic Test: complete blood picture; complete blood picture

Outcome Measures

Primary Outcome Measures

1. lymphocyte count in immune thrombocytopenic purpura [15 minutes]

   intital lymphocyte counts predictive value in immune thrombocytopenic purpura by complete blood picture

Eligibility Criteria

Criteria

• Ages Eligible for Study: N/A and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Newly diagnosed cases of primary ITP , adults and children.

Exclusion Criteria:

• Cases of secondary ITP

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Assiut University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Dolagy nabil naguib, principle investigator, Assiut University
• ClinicalTrials.gov Identifier: NCT03244410
• Other Study ID Numbers: LCITP
• First Posted: Aug 9, 2017
• Last Update Posted: Aug 9, 2017
• Last Verified: Aug 1, 2017

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Purpura; Purpura, Thrombocytopenic; Purpura, Thrombocytopenic, Idiopathic

Study Results

No Results Posted as of Aug 9, 2017